Table I.

Activity of Ispinesib against the PPTP in Vitro Panel

Cell Line	Status	Histology	T/C% at1 μM	IC50(nM)
RD		Rhabdomyosarcoma	11.4	5.8
Rh41	Post-Therapy	Rhabdomyosarcoma	22.8	11.1
Rh18	Diagnosis	Rhabdomyosarcoma	71.2	>1000
Rh30	Diagnosis	Rhabdomyosarcoma	19.4	8.0
BT-12	Diagnosis	Rhabdoid	6.2	2.1
CHLA-266	Diagnosis	Rhabdoid	25.8	1.1
TC-71	Post-Therapy	Ewing sarcoma	0.3	4.1
CHLA-9	Diagnosis	Ewing sarcoma	0.9	2.8
CHLA-10	Post-Therapy	Ewing sarcoma	2.2	3.6
CHLA-258	Post-Bone Marrow Transplant	Ewing sarcoma	12.8	4.8
SJ-GBM2	Post-Therapy	Glioblastoma	13.5	0.5
NB-1643	Diagnosis	Neuroblastoma	9.9	3.0
NB-EBc1	Post-Therapy	Neuroblastoma	6.5	11.4
CHLA-90	Post-Bone Marrow Transplant	Neuroblastoma	11.6	3.6
CHLA-136	Post-Bone Marrow Transplant	Neuroblastoma	14.9	7.0
NALM-6	Post-Therapy	ALL	0.0	1.6
COG-LL-317	Post-Therapy	ALL	0.1	2.5
RS4; 11	Post-Therapy	ALL	0.2	0.6
MOLT-4	Post-Therapy	ALL	0.1	7.9
CCRF-CEM		ALL	0.1	3.0
Kasumi-1	Post-Bone Marrow Transplant	AML	9.4	11.9
Karpas-299	Post-Therapy	ALCL	4.3	8.9
Ramos-RA1		NHL	0.0	8.0
Median			6.5	4.1
Minimum			0.0	0.5
Maximum			71.2	>1000